162 related articles for article (PubMed ID: 25358590)
1. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer.
Vermassen T; Van Praet C; Lumen N; Decaestecker K; Vanderschaeghe D; Callewaert N; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Prostate; 2015 Feb; 75(3):314-22. PubMed ID: 25358590
[TBL] [Abstract][Full Text] [Related]
2. Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer.
Vermassen T; Van Praet C; Vanderschaeghe D; Maenhout T; Lumen N; Callewaert N; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Electrophoresis; 2014 Apr; 35(7):1017-24. PubMed ID: 24254641
[TBL] [Abstract][Full Text] [Related]
3. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
[TBL] [Abstract][Full Text] [Related]
4. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
[TBL] [Abstract][Full Text] [Related]
5. Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile.
Vermassen T; D'Herde K; Jacobus D; Van Praet C; Poelaert F; Lumen N; Callewaert N; Decaestecker K; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
J Clin Pathol; 2017 Oct; 70(10):838-846. PubMed ID: 28360190
[TBL] [Abstract][Full Text] [Related]
6. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
[TBL] [Abstract][Full Text] [Related]
7. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
8. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis.
Vermassen T; Van Praet C; Poelaert F; Lumen N; Decaestecker K; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Biochem Med (Zagreb); 2015; 25(3):439-49. PubMed ID: 26526330
[TBL] [Abstract][Full Text] [Related]
10. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers.
Ma W; Diep K; Fritsche HA; Shore N; Albitar M
Genet Test Mol Biomarkers; 2014 Mar; 18(3):156-63. PubMed ID: 24512523
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic value of complexed prostate-specific antigen for prostate cancer].
Su HW; Li Y; Xu P
Zhonghua Nan Ke Xue; 2003 Sep; 9(6):431-3. PubMed ID: 14574807
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of lipids, total antioxidants, and trace metals in benign prostate hyperplasia and prostate cancer.
Adedapo KS; Arinola OG; Shittu OB; Kareem OI; Okolo CA; Nwobi LN
Niger J Clin Pract; 2012; 15(3):293-7. PubMed ID: 22960963
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
15. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer antigen-1 as a potential novel marker for prostate cancer.
Liu BQ; Wu YD; Li PH; Wei JX; Zhang T; Liu RL
Asian J Androl; 2007 Nov; 9(6):821-6. PubMed ID: 17968469
[TBL] [Abstract][Full Text] [Related]
17. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin-binding patterns.
Janković MM; Kosanović MM
Clin Biochem; 2005 Jan; 38(1):58-65. PubMed ID: 15607318
[TBL] [Abstract][Full Text] [Related]
18. Glycosylation of prostate specific antigen and its potential diagnostic applications.
Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR
Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018
[TBL] [Abstract][Full Text] [Related]
19. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
20. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer.
Byun YJ; Piao XM; Jeong P; Kang HW; Seo SP; Moon SK; Lee JY; Choi YH; Lee HY; Kim WT; Lee SC; Cha EJ; Yun SJ; Kim WJ
Investig Clin Urol; 2021 May; 62(3):340-348. PubMed ID: 33834642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
